Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
39.46
-0.05 (-0.13%)
At close: Apr 28, 2026, 4:00 PM EDT
39.45
-0.02 (-0.04%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Centessa Pharmaceuticals stock have an average target of 43.17, with a low estimate of 35 and a high estimate of 62. The average target predicts an increase of 9.40% from the current stock price of 39.46.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 5 | 4 | 3 | 2 |
| Buy | 4 | 5 | 5 | 6 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 2 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 11 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $35 → $42 | Buy → Hold | Downgrades | $35 → $42 | +6.44% | Apr 20, 2026 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 2, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $36 → $40 | Buy → Hold | Downgrades | $36 → $40 | +1.37% | Apr 1, 2026 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 31, 2026 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 31, 2026 |
Financial Forecast
Revenue This Year
n/a
from 15.00M
Revenue Next Year
n/a
EPS This Year
-1.76
from -1.46
EPS Next Year
-1.87
from -1.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.69 | -1.21 | ||||||
| Avg | -1.76 | -1.87 | ||||||
| Low | -2.12 | -2.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.